Sanara MedTech Inc. 8-K

What Happened

• Sanara MedTech Inc. announced results of its Annual Meeting of Shareholders held June 4, 2026. A total of 6,701,593 shares were present in person or by proxy.
• All nine director nominees were elected to one-year terms (through the 2027 annual meeting). Vote tallies showed support ranging from about 5.08 million to 5.39 million votes “for” each nominee, with broker non-votes of 1,296,806.
• Shareholders ratified Weaver and Tidwell, L.L.P. as the Company’s independent auditors for fiscal 2026 (6,696,035 for; 2,198 against; 3,360 abstentions).
• The advisory Say-on-Pay (approval of named executive officer compensation) passed (5,280,546 for; 57,530 against; 66,711 abstentions). Shareholders also voted on the frequency of future advisory votes, and a three-year frequency received the most votes (3,296,133 reported for three years; final board determination: every three years).

Key Details

• Shares present/voting: 6,701,593.
• Director votes example: Seth D. Yon — 5,390,547 for, 14,240 withheld; broker non-votes: 1,296,806 (same broker non-vote total for all director elections).
• Auditor ratification: 6,696,035 for; 2,198 against; 3,360 abstain.
• Advisory votes: Say-on-Pay — 5,280,546 for; Frequency vote — three years received the plurality and the Board adopted a three-year cycle (next frequency vote expected in 2029).

Why It Matters

• The re-election of the board and ratification of the auditor provide continuity in governance and oversight, which can affect strategic direction and financial reporting stability.
• Passing the advisory Say-on-Pay indicates shareholder support for executive compensation practices; the non-binding three-year frequency decision means the company will hold future advisory votes on executive pay every three years (next expected in 2029).
• Broker non-votes (1,296,806) show a portion of shares were not voted on certain matters, which can affect vote outcomes where broker discretionary voting is not permitted.